Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSLV-145 + tenecteplase
- Development stage
- Preclinical
- Lead developer
- Resolve Therapeutics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
RSLV-145 + tenecteplase is an investigational combination therapy being evaluated for the treatment of acute ischemic stroke (AIS). RSLV-145 is a bispecific RNase/DNase-Fc fusion protein developed by Resolve Therapeutics that degrades extracellular RNA and DNA, specifically targeting neutrophil extracellular traps (NETs) which are associated with resistance to thrombolysis and poor clinical outcomes in stroke. Tenecteplase is a recombinant fibrin-specific tissue plasminogen activator (tPA) that converts plasminogen to plasmin to dissolve blood clots. By combining RSLV-145 with tenecteplase, the therapy aims to digest NETs within thrombi to restore thrombolytic efficacy and degrade extracellular RNA to limit reperfusion injury, thereby improving clinical outcomes in acute ischemic stroke.
- Other names
- RSLV 145 + MetalyseRSLV 145 + TNKaseRSLV 145 + tenecteplaseRSLV145 + MetalyseRSLV145 + TNKaseRSLV145 + tenecteplaseRSLV-145 + MetalyseRSLV-145 + TNKase
02
Targets
Actin filament proteinseDNA (Extracellular DNA)Fibrin (Factor Ia)NET (Norepinephrine Transporter)PLG (Plasminogen)
Beyond the preview
Go deeper on RSLV-145 + tenecteplase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSLV-145 + tenecteplase.